Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacologic Augmentation of TMS for Depression With D-serine
NCT06876129Phase 1Recruiting
- Sponsor
- McLean Hospital
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, double-blind trial of d-serine in major depressive disorder (MDD) (2 arms), sponsored by McLean Hospital. Primary endpoint: Patient Health Questionnaire 9. Started Apr 2025; status: recruiting.
02
Drugs
d-serine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06876129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06876129.